Dynamics of NITs (LIVERFASt, FIB-4, VCTE) during monitoring therapy with Resmetirom in patients with MASH — update
Dynamics of NITs (LIVERFASt, FIB-4, VCTE) during monitoring therapy with Resmetirom in patients with MASH — update
Noninvasive initiation and monitoring of Resmetirom therapy using LIVERFASt, FIB-4 and VCTE in patients with MASH
Noninvasive initiation and monitoring of Resmetirom therapy using LIVERFASt, FIB-4 and VCTE in patients with MASH
The utility of NITs — LIVERFASt, FIB-4 and VCTE — in the initiation and monitoring of Resmetirom therapy in MASH patients (initial cohort)
The utility of NITs — LIVERFASt, FIB-4 and VCTE — in the initiation and monitoring of Resmetirom therapy in MASH patients (initial cohort)
Simulating clinical confidence intervals for black-box algorithmic predictions of liver steatosis
Simulating clinical confidence intervals for black-box algorithmic predictions of liver steatosis
Long-term prognosis of MAFLD patients according to non-invasive methods
Long-term prognosis of MAFLD patients according to non-invasive methods
Noninvasive LIVERFASt transition rate to liver fibrosis, similar to liver biopsy in NAFLD patients
Noninvasive LIVERFASt transition rate to liver fibrosis, similar to liver biopsy in NAFLD patients
Repeated noninvasive liver biopsy surrogate LIVERFASt correlates with BMI and liver enzyme improvements (regression poster)
Repeated noninvasive liver biopsy surrogate LIVERFASt correlates with BMI and liver enzyme improvements
Application of LIVERFASt biomarkers to evaluate longitudinal hepatic fibrosis and inflammation after HCV cure
Application of LIVERFASt biomarkers to evaluate longitudinal hepatic fibrosis and inflammation after HCV cure